Zydus Lifesciences Limited (formerly Cadila Healthcare) has got the United States Food and Drug Administration (USFDA) final approval to market Topiramate Extended-Release Capsules, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg.
Topiramate Extended-Release capsule is used to treat and prevent seizures in people who have epilepsy. It can also be used to prevent migraines. The drug will be produced at the group's formulation manufacturing facility in Ahmedabad Special Economic Zone, India.
According to IQVIA data, Topiramate Extended-Release capsule had annual sales of USD 68.8 million in the United States.
Since the beginning of the filing process in FY 2003-04, the group has received 335 approvals and has filed over 431 ANDAs.
At around 9.18 AM, Zydus Lifesciences was trading at Rs412 up by 0.62% from its previous closing of Rs409.45 on the BSE.
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
